Kailera Therapeutics CLO reports stock option holdings
Kailera Therapeutics, Inc. disclosed the stock option holdings of its Chief Legal Officer, Scott Akamine.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Kailera Therapeutics, Inc. disclosed the stock option holdings of its Chief Legal Officer, Scott Akamine. He holds options to buy 193,999 shares of common stock at an exercise price of $7.24 per share, expiring on November 5, 2035.
He also holds options tied to 143,673 and 213,890 underlying shares at an exercise price of $5.25 per share, both expiring on December 9, 2034. These options vest 25% on specified initial vesting dates, then in 36 monthly installments, subject to his continued service with the company.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Akamine Scott
Role
Chief Legal Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 551,562 contracts (Direct)
Footnotes (3)
- F1. The options vested and became exercisable as to 25% of the total shares on November 12, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
- F2. The options vested and became exercisable as to 25% of the total shares on December 9, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
- F3. The options vest and become exercisable as to 25% of the total shares on November 5, 2026 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Option exercise price: $7.24/share
Underlying shares at $7.24: 193,999 shares
Option exercise price: $5.25/share
+4 more
7 metrics
Option exercise price
$7.24/share
Stock option on common stock, expires November 5, 2035
Underlying shares at $7.24
193,999 shares
Common stock underlying a stock option, direct holding
Option exercise price
$5.25/share
Two stock option grants expiring December 9, 2034
Underlying shares at $5.25 (grant 1)
143,673 shares
Common stock underlying a stock option, direct holding
Underlying shares at $5.25 (grant 2)
213,890 shares
Common stock underlying a stock option, direct holding
Vesting structure
25% initial, then 36 monthly installments
Vesting schedule subject to continued service
Initial vesting dates
Nov 12 2025, Dec 9 2025, Nov 5 2026
25% of total shares vest on each respective date
Key Terms
Stock Option (right to buy), exercise price, expiration date, underlying security, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 7.2400 and 5.2500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2034-12-09 and 2035-11-05"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: Common Stock"
vesting financial
"The options vested and became exercisable as to 25% of the total shares..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Akamine Scott Form 3 for KLRA show?
The Form 3 for Kailera Therapeutics (KLRA) shows Chief Legal Officer Scott Akamine’s existing stock option holdings. It lists several option grants, including exercise prices, expiration dates, and how many common shares each grant could convert into if exercised.
What are the exercise prices on Scott Akamine’s KLRA stock options?
Scott Akamine’s reported options include exercise prices of $7.24 and $5.25 per share. The exercise price is the fixed amount he would pay per share if he decides to exercise the options and convert them into Kailera Therapeutics common stock.
When do Scott Akamine’s Kailera Therapeutics options expire?
The reported options have expiration dates on December 9, 2034 and November 5, 2035. After these dates, any unexercised options lapse and can no longer be used to buy Kailera Therapeutics common shares, limiting how long the insider can act on these rights.
How do Scott Akamine’s KLRA options vest over time?
Each option grant vests 25% on an initial date, then in 36 substantially equal monthly installments. Vesting is subject to his continued service on each vesting date, meaning he earns the right to exercise more options gradually while remaining with Kailera Therapeutics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates